The remarkable increase in the number of antibody therapeutics in late-stage clinical studies that occurred between 2010 and 2022 has been documented in the ‘Antibodies to watch‘ article series, which describes monoclonal antibodies in late-stage clinical studies (i.e., pivotal Phase 2, Phase 2/3 or Phase 3). All articles in the series were published in mAbs, and they are all freely available.
The table below is derived from data included in the latest article in the series, Antibodies to Watch in 2024, published in January 2023. The Antibody Society will update the data every quarter during 2023. Last table update: June 19, 2024.
Data for antibody therapeutic products that have advanced to regulatory review or approval in any country have been excluded from this table, but they are included in a searchable table that can be found here.
Biosimilar antibodies have been excluded from both tables.
Format and Fc modification data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.
Please cite our data as follows: The Antibody Society. Antibody therapeutics in late-stage clinical studies. (date accessed); www.antibodysociety.org/antibodies-in-late-stage-clinical-studies/
The table below is an interactive table that can be filtered based on multiple conditions. Please use the filtering criteria above the table and type in the search boxes in the header of each column.
Scroll right to see all the columns.
Drug Code(s) | INN | Target | Format | Specificity | Sequence source | Backbone | Light Chain | Conjugated/Fused | Linker | Payload/Fused moiety | Fc Mutations/Modifications | Phase of Clinical Development | Late-stage Clinical Study Indications | Therapeutic Area | Company | Licensee/Partner |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9MW0211 | VEGF-A | Full length Ab | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 2/3 | Wet age-related macular degeneration | Ophthalmic disorders | Mabwell (Shanghai) Bioscience Co. Ltd. | Apexigen | |||
9MW2821 | Nectin-4 | TBD | Monospecific | Humanized | TBD | TBD | ADC | Valine-Citrulline (Cleavable linker) | MMAE | TBD | Phase 3 | Urothelial carcinoma (NCT06196736 / CTR20234024) | Cancer | Mabwell (Shanghai) Bioscience Co. Ltd. | ||
AB154 | Domvanalimab | TIGIT | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | L234A, L235A (impair Fc effector functions) | Phase 3 | Gastrointestinal tract adenocarcinoma (NCT05568095); Non-small cell lung cancer (NCT05211895, NCT05502237, NCT04736173) | Cancer | Arcus Biosciences Inc. | Gilead Sciences, Taiho Pharma | ||
ABBV-151, ARGX-115, PR-1762844 | Livmoniplimab | GARP/TGF beta complex | Full length Ab | Monospecific | Chimeric / Humanized | IgG4 | kappa | Unconjugated | S228P (hinge stabilization) | Phase 2/3 | Non-small cell lung cancer (NCT06236438) | Cancer | argenx | Eli Lilly and Company | ||
ABBV-181 | Budigalimab | PD-1 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | L234A, L235A (impair Fc effector functions) | Phase 2/3 | Non-small cell lung cancer (NCT06236438) | Cancer | AbbVie | |||
ABBV-383, TNB-383B | BCMA, CD3 | TBD | Bispecific | Human | TBD | TBD | Unconjugated | TBD | Phase 3 | Multiple myeloma (NCT06158841) | Cancer | Amgen | AbbVie | |||
ABBV-399 | Telisotuzumab vedotin | cMET | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Valine–citrulline (Cleavable linker) | MMAE | K222C T223del T225del K447del | Phase 3 | Non-small cell lung cancer (NCT04928846, NCT06093503 not yet recruiting) | Cancer | AbbVie | |
ABBV-IMAB-TJC4, TJ011133, TJ133, TJC4 | Lemzoparlimab | CD47 | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Myelodysplastic Syndromes (MDS) (NCT05709093) | Cancer | I-Mab Biopharma Co. Ltd. | |||
ABC008 | Ulviprubart | KLRG1 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | Afucosylated (improve FcγRIIIa binding/improve ADCC) | Phase 2/3 | Inclusion Body Myositis (NCT05721573, NCT06450886 not yet recruiting) | Immune-mediated / inflammatory disorders | Abcuro Inc. | |||
ACT017 | Glenzocimab | GP VI | Fragment - Fab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 2/3 | Acute ischemic stroke (NCT05070260, NCT05559398) | Cardiovascular / hemostasis disorders | Acticor Biotech | |||
ACU193 | Sabirnetug | Amyloid beta (oligomers) | Full length Ab | Monospecific | Humanized | IgG2 | kappa | Unconjugated | None found | Phase 2/3 | Alzheimer's disease (NCT06335173) | Neurological disorders | Acumen Pharmaceuticals Inc. | |||
AGEN1181 | Botensilimab | CTLA-4 | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | S239D, A330L, I332E (enhanced effector function) | Phase 2 pivotal | Colorectal cancer (NCT05608044) | Cancer | Agenus Inc. | |||
AGEN2034 | Balstilimab | PD-1 | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 2 pivotal | Metastatic Colorectal Cancer (NCT05608044) | Cancer | Agenus Inc. | Betta Pharmaceuticals, Recepta biopharma | ||
AK111 | Gumokimab | IL-17A | Full length Ab | Monospecific | TBD | IgG1 | kappa | Unconjugated | None found | Phase 3 | Plaque psoriasis (CTR20230111); ankylosing spondylitis (NCT06378697) | Immune-mediated / inflammatory disorders | Akesobio Australia Pty Ltd | |||
AK120 | Manfidokimab | IL-4R alpha | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Atopic dermatitis (NCT06383468) | Immune-mediated / inflammatory disorders | Akesobio Australia Pty Ltd | |||
ALXN1720 | Gefurulimab | Complement C5, albumin | Fragment - sdAb, VHH-VHH' | Bispecific | Humanized | NA | NA | Unconjugated | NA | Phase 3 | Generalized myasthenia gravis (NCT05556096) | Immune-mediated / inflammatory disorders | AstraZeneca | |||
ALXN2220, NI006, NI301A | Amyloid transthyretin | Full length Ab | Monospecific | Human | IgG1 | TBD | Unconjugated | TBD | Phase 3 | Transthyretin amyloid cardiomyopathy (NCT06183931) | Cardiovascular / hemostasis disorders | Neurimmune AG | AstraZeneca | |||
ANB019 | Imsidolimab | IL-36R | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Generalized pustular psoriasis (NCT05352893, NCT05366855) | Immune-mediated / inflammatory disorders | AnaptysBio Inc. | |||
AntiBKV, MTX-005, mAb129 | BK virus | Full length Ab | Monospecific | Human | TBD | TBD | Unconjugated | TBD | Phase 2/3 | BK Viremia (NCT05769582) | Infectious diseases | Memo Therapeutics AG | ||||
ANX005 | Complement C1q | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | None found | Phase 3 | Guillain-Barré syndrome (NCT04701164) | Muscular disorders | Annexon Inc. | ||||
AR-301, KBSA301 | Tosatoxumab | S. aureus alpha toxin | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | None found | Phase 3 | Ventilator-associated pneumonia caused by S. aureus (NCT03816956) | Infectious diseases | Kenta Biotech Ltd | Aridis Pharmaceuticals, Serum AMR, Shenzhen Arimab Biopharmaceuticals Co. Ltd. | ||
ARX788, JNJ-0683, NCB-001 | Anvatabart opadotin | HER2 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Oxime (Non-cleavable linker) | Amberstatin 269 (Auroxime) | A114pAF (non-natural amino acid for site specific conjugation) | Phase 3 | Breast cancer (NCT05426486) | Cancer | Johnson & Johnson | NovoCodex, Zhejiang Medicine Co. Ltd |
ASKB589 | Claudin-18.2 | Full length Ab | Monospecific | Humanized | IgG1 | TBD | Unconjugated | TBD | Phase 3 | Gastric or gastroesophageal junction adenocarcinoma (NCT06206733 / CTR20233416) | Cancer | Jiangsu Aosaikang Pharmaceutical Co. Ltd. | ||||
AV299, SCH900105 | Ficlatuzumab | HGF | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Head and neck cancer (NCT06064877) | Cancer | LG Chem Ltd. | Biodesix | ||
AZD0901, CMG901, MRG005 | Claudin-18.2 | Full length Ab | Monospecific | TBD | TBD | TBD | ADC | Cleavable linker | MMAE | TBD | Phase 3 | Gastric Cancer and Gastroesophageal Junction Cancer (NCT06346392) | Cancer | LEPU Biopharma, Shanghai Miracogen Inc. | AstraZeneca, Keymed Biosciences Inc. | |
AZD2936 | Rilvegostomig | PD-1, TIGIT | Full length Ab | Bispecific | Humanized | IgG1 | kappa/lambda | Unconjugated | L234F/L235E/P331S (reduced effector function), S354C/T366W (knob) and Y349C/T366S/L368A/Y407V (hole) (heavy chain heterodimerization) | Phase 3 | Biliary tract cancer (NCT06109779) | Cancer | AstraZeneca | Compugen Ltd. | ||
AZD3152 | Sipavibart | SARS-CoV-2 (spike protein) | Full length Ab | Monospecific | TBD | IgG1 | lambda | Unconjugated | Long Acting Antibodies (LAAB); Reduce Fc effector function (L234F L235E P331S) and extend half-life ( M252Y S254T T256E) | Phase 3 | Pre-exposure prophilaxis of COVID-19 (NCT05648110) | Infectious diseases | AstraZeneca | RQ Biotechnology | ||
BAT1308 | PD-1 | Full length Ab | Monospecific | Humanized | IgG4 | TBD | Unconjugated | TBD | Phase 2/3 | Cervical cancer (NCT06123884 / CTR20232394) | Cancer | Bio-Thera Solutions Ltd. | ||||
BAT4406F | CD20 | Full length Ab | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 2/3 | Neuromyelitis optica spectrum disorder (CTR20231610) | Immune-mediated / inflammatory disorders | Bio-Thera Solutions Ltd. | ||||
BAT5906 | VEGF-A | Full length Ab | Monospecific | TBD | IgG1 | kappa | Unconjugated | None found | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (NCT05439629) | Ophthalmic disorders | Bio-Thera Solutions Ltd. | ||||
BGB-A1217 | Ociperlimab | TIGIT | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Non-small cell lung cancer (NCT04746924, NCT04866017) | Cancer | BeiGene Ltd. | |||
BIIB059 | Litifilimab | BDCA2 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Cutaneous lupus erythematosus (NCT05531565); Systemic lupus erythematosus (NCT05352919, NCT04961567, NCT04895241) | Immune-mediated / inflammatory disorders | Biogen | |||
BL-B01D1 | Izalontamab brengitecan | EGFR, HER3 | Appended Ig - 2+2 symmetric, IgG-(scFv)2 | Bispecific | TBD | IgG1 | kappa/lambda | ADC | Cathepsin B (Cleavable linker) | Ed-04 (topoisomerase I inhibitor) | None found | Phase 3 | Nasopharyngeal carcinoma (NCT06118333 / CTR20233419); Esophageal Squamous Cell Carcinoma (NCT06304974) | Cancer | Sichuan Baili Pharmaceutical Co. Ltd., Systimmune | Bristol Myers Squibb |
BL-M07D1 | HER2 | TBD | Monospecific | TBD | TBD | TBD | ADC | Undisclosed | Undisclosed | TBD | Phase 3 | Breast cancer (NCT06316531 /CTR20240858) | Cancer | Sichuan Baili Pharmaceutical Co. Ltd., Systimmune | ||
BNT316, ONC-392 | Gotistobart | CTLA-4 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | M252Y, S254T, T256E (half-life extension); S298A, E333A, K334A (enhanced ADCC) | Phase 3 | Non-small cell lung cancer (NCT05671510) | Cancer | OncoC4 Inc. | BioNTech SE | ||
CAEL-101, Ch mAb 11-1F4 | Anselamimab | Amyloid light chain | Full length Ab | Monospecific | Chimeric | IgG1 | kappa | Unconjugated | None found | Phase 3 | Light chain (AL) amyloidosis (NCT04512235, NCT04504825) | Immune-mediated / inflammatory disorders | AstraZeneca | |||
CBP-201 | Rademikibart | IL-4R alpha | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 2 pivotal | Atopic dermatitis (NCT05017480) | Immune-mediated / inflammatory disorders | Suzhou Connect Biopharmaceuticals Ltd. | Simcere Pharmaceutical Co. Ltd | ||
CBT-501, GB226, Genolimzumab (not WHO assigned INN), APT-501 | Geptanolimab | PD-1 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Cervical cancer (NCT03808857) | Cancer | Genor BioPharma Co. Ltd | CBT Pharmaceuticals Inc., Apollomics (Australia) Pty. Ltd. | ||
CC-93538, RPC4046; ABT-308, 13C5.5 | Cendakimab | IL-13 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | L234A, L235A (impair Fc effector functions) | Phase 3 | Eosinophilic gastroenteritis (NCT05214768); Eosinophilic esophagitis (NCT04753697, NCT04991935) | Immune-mediated / inflammatory disorders | AbbVie | Bristol Myers Squibb | ||
CDP-7657 | Dapirolizumab pegol | CD40L | Fragment conjugate - Fab, pegylated | Monospecific | Humanized | IgG1 | kappa | Immunoconjugate, Pegylated | PEG | None found | Phase 3 | Systemic lupus erythematosus (NCT04976322, NCT04294667) | Immune-mediated / inflammatory disorders | UCB Biopharma | Biogen | |
COR-001, WBP216 , MEDI5117 | Ziltivekimab | IL-6 | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | M252Y, S254T, T256E (half life extension) | Phase 3 | Atherosclerotic cardiovascular disease, chronic kidney disease (NCT05021835); Heart Failure (NCT05636176) | Cardiovascular / hemostasis disorders | AstraZeneca | Novo Nordisk | ||
CS1003 | Nofazinlimab | PD-1 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Hepatocellular carcinoma (NCT04194775) | Cancer | Cstone Pharma | EQRx | ||
CSL300, ALD518; BMS-945429 | Clazakizumab | IL-6 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | N297A (Fc-aglycosylated) | Phase 3 | Antibody-mediated rejection in kidney transplant recipients (NCT03744910); Atherosclerotic Cardiovascular Disease, End-stage kidney disease (NCT05485961) | Immune-mediated / inflammatory disorders | H. Lundbeck A/S | Vitaeris | ||
DB-1303, BNT323 | HER2 | Full length Ab | Monospecific | TBD | IgG1 | TBD | ADC | Enzymatically cleavable peptide linker | P1003 topoisomerase I inhibitor | TBD | Phase 3 | Breast cancer (NCT06265428); Endometrial cancer (NCT06340568 not yet recruiting) | Cancer | Duality Biologics (Suzhou) Co. Ltd. | BioNTech SE | |
DP303c | HER2 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Cleavable linker | MMAE | None found | Phase 3 | Breast cancer (NCT05901935) | Cancer | CSPC Pharmaceutical Group Limited | ||
DS-7300a | Ifinatamab deruxtecan | B7-H3 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Glycine-Glycine-Phenylalanine-Glycine (GGFG; Tetrapeptide-based cleavable linker) | DXd/DX8951 (MAAA-1181a) (Topoisomerase I inhibitor) | None found | Phase 3 pending | Small cell lung cancer (NCT06236438) | Cancer | Daiichi Sankyo Co. Ltd | Merck Sharp & Dohme |
DS-6000A | Raludotatug deruxtecan | Cadherin-6 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Glycine-Glycine-Phenylalanine-Glycine (GGFG; Cleavable linker) | DXd/DX8951 (MAAA-1181a) (Topoisomerase I inhibitor) | None found | Phase 2/3 | Ovarian cancer (NCT06161025) | Cancer | Daiichi Sankyo Co. Ltd | Merck |
E2814 | Etalanetug | Tau (MTBR) | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 2/3 | Dominantly inherited Alzheimer's Disease (NCT05269394, NCT01760005) | Neurological disorders | Eisai Inc. | University College London | ||
EB05, NI-0101 | Paridiprubart | TLR4 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | N325S, L328F (abrogates C1q and FcγRIII binding, increases FcγRII binding, retains FcγRI high affinity binding) | Phase 2/3 | COVID-19-related acute respiratory distress syndrome (NCT04401475) | Immune-mediated / inflammatory disorders | NovImmune SA | Edesa Biotech, Genentech | ||
ES104, CTX-009, TR009, NOV1501, ABL001 | DLL4, VEGF-A | Appended Ig - scFv-scFv-Full-length antibody | Bispecific | TBD | TBD | TBD | Unconjugated | Phase 2/3 | Biliary tract cancers (NCT05506943) | Cancer | National OncoVenture | Compass Therapeutics Inc., Elpiscience Biopharmaceuticals, ABL Bio Inc. | ||||
F520 | Rulonilimab | PD-1 | Full length Ab | Monospecific | Chimeric | IgG1 | kappa | Unconjugated | N297A (Fc-aglycosylated); T250Q, M428L (half life extension) | Phase 2/3 | Hepatocellular carcinoma (NCT05408221) | Cancer | Shandong New Time Pharmaceutical Co. LTD | |||
FG-3019 | Pamrevlumab | Connective tissue growth factor | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 3 | Duchenne muscular dystrophy (NCT04632940, NCT04371666); Idiopathic pulmonary fibrosis (NCT04419558, NCT03955146); Pancreatic cancer (NCT03941093, NCT04229004) | Cancer | FibroGen | Bristol Myers Squibb | ||
FG-M108, M108 | Claudin-18.2 | TBD | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 3 | Gastric or gastroesophageal junction adenocarcinoma (NCT06177041) | Cancer | FutureGen Biopharmaceutical (Beijing) Co. Ltd | ||||
FPA144 | Bemarituzumab | FGFR2b | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | Afucosylated (improve FcγRIIIa binding/improve ADCC) | Phase 3 | Gastric cancer/gastroesophageal junction adenocarcinoma (NCT05111626, NCT05052801) | Cancer | Amgen | Zai Lab | ||
FUB523, BION-1301 | Zigakibart | APRIL | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | IgA nephropathy (NCT05852938) | Immune-mediated / inflammatory disorders | Novartis Pharmaceuticals | |||
GMA-102 (diabetes indication), GMA-105 (obesity indication), Glutazumab (not WHO assigned INN) | Gulgafafusp alfa | GLP-1R | Full length Ab | Monospecific | Humanized | IgG2 | TBD | Immunoconjugate | GLP-1 peptide | None found | Phase 3 | Type 2 diabetes (CTR20222558, CTR20211661) | Metabolic disorders | Gmax Biopharm Australia Pty Ltd | ||
GR1801 | Silevimig | Rabies virus (glycoprotein) | Fragment-Fc - scFv-Fc-Fab | Bispecific | Human | IgG1 | TBD | Unconjugated | None found | Phase 3 | Rabies (NCT05846568) | Infectious diseases | Genrix (Shanghai) Biopharmaceutical Co. Ltd. | |||
GR1802, GR-1802 | IL-4R alpha | TBD | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 3 | Atopic dermatitis (NCT06216392 / CTR20233857) | Immune-mediated / inflammatory disorders | Genrix (Shanghai) Biopharmaceutical Co. Ltd. | ||||
GSK3511294 | Depemokimab | IL-5 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | M252Y, S254T, T256E (half-life extension) | Phase 3 | Hypereosinophilic syndrome (NCT05334368); Eosinophilic granulomatosis with polyangiitis (NCT05263934); Nasal polyps (NCT05274750, NCT05281523); Severe uncontrolled asthma with an eosinophilic phenotype (NCT05243680, NCT04719832, NCT04718103, NCT04718389) | Immune-mediated / inflammatory disorders | GSK | |||
GSK4069889, TSR-022 | Cobolimab | TIM3 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 2/3 | Non-small cell lung cancer (NCT04655976) | Cancer | GSK | |||
GSK4428859, EOS884448, EOS-448, RCA-2 | Belrestotug | TIGIT | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 3 | Non-small cell lung cancer | Cancer | iTEOS Therapeutics | GSK | ||
GSK4527226, AL001 | Latozinemab | Sortilin | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | L234A, L235A, P331S (remove Fc effector functions) | Phase 3 | Frontotemporal dementia (NCT04374136) | Neurological disorders | Alector Inc. | GSK | ||
HB0017 | IL-17A | TBD | Monospecific | Humanized | IgG1 | TBD | Unconjugated | TBD | Phase 3 | Plaque psoriasis (CTR20240521) | Immune-mediated / inflammatory disorders | Huabo Biopharm Co. Ltd. | ||||
I-131-BC8 | Apamistamab-Iodine (131I) | CD45 | Full length Ab | Monospecific | Murine | IgG1 | kappa | RIC | I-131 | None found | Phase 3 | Acute myeloid leukemia (NCT02665065) | Cancer | Actinium Pharmaceuticals | Immedica AB | |
IAH0968 | HER2 | Full length Ab | Monospecific | TBD | TBD | TBD | Unconjugated | Afucosylated (improve FcγRIIIa binding/improve ADCC) | Phase 2/3 | Colorectal Cancer (NCT05673512) | Cancer | SUNHO (China) BioPharmaceutical Co. Ltd., Beijing Sunho Pharmaceutical Co. | ||||
IBI112 | Picankibart | IL-23p19 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | M252Y, S254T, T256E (half life extension) | Phase 3 | Psoriasis (NCT05645627) | Immune-mediated / inflammatory disorders | Innovent Biologics (Suzhou) Co. Ltd. | |||
IBI343 | Claudin-18.2 | TBD | Monospecific | TBD | TBD | TBD | ADC | Undisclosed | Undisclosed | TBD | Phase 3 pending | Gastric or gastroesophageal junction adenocarcinoma (NCT06238843) | Cancer | Innovent Biologics (Suzhou) Co. Ltd. | ||
IKS014, LCB14-0110, FS-1502, Trastuzumab mafodotin | HER2 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | β-glucuronidase (BG; Cleavable linker | MMAF | C terminal CaaX sequence for site specific conjugation | Phase 3 | Breast cancer (NCT05755048) | Cancer | LegoChem Biosciences Inc. | IKSUDA Therapeutics, Shanghai Fosun Pharmaceutical Development Co Ltd. | |
IMC-F106C | PRAME, CD3 | Fragment fusion - scFv-TCR | Bispecific | TBD | NA | TBD | Immunoconjugate | T cell receptor | NA | Phase 3 | Melanoma (NCT06112314) | Cancer | Immunocore Ltd | |||
IMGN632 | Pivekimab sunirine | CD123 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Alanine-Alanine (Cleavable linker) | DGN549 IGN | S442C (site-specific conjugation) | Phase 2 pivotal | Blastic plasmacytoid dendritic cell neoplasm (NCT03386513 CADENZA) | Cancer | ImmunoGen | |
JCT205, INBRX-109 | Ozekibart | DR5 | Fragment-Fc - (VHH-VHH)2-Fc | Monospecific | Humanized | TBD | NA | Unconjugated | E233>del,L234>del, L235>del (reduced effector function: CDC and ADCC) | Phase 2 pivotal | Conventional Chondrosarcoma (NCT04950075) | Cancer | Inhibrx Biosciences Inc. | Transcenta Holding Limited | ||
JMT101 | Becotatug | EGFR | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 2 pivotal | Non-small cell lung cancer (CTR20212469) | Cancer | CSPC Pharmaceutical Group Limited | |||
JNJ-63723283 | Cetrelimab | PD-1 | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Bladder cancer (NCT04658862, NCT05714202) | Cancer | Janssen Research & Development LLC | Xoma | ||
JNJ-80202135, M281 | Nipocalimab | FcRn | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | N297A (Fc-aglycosylated) | Phase 3 | Warm autoimmune hemolytic anemia (NCT04119050); Generalized myasthenia gravis (NCT05265273, NCT04951622) ; Polyradiculoneuropathy (NCT05327114) | Immune-mediated / inflammatory disorders | Janssen Research & Development LLC | |||
JS004, TAB004 | Tifcemalimab | BTLA | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge stabilization) | Phase 3 | Small cell lung cancer (NCT06095583) | Cancer | Shanghai Junshi Bioscience Co Ltd | |||
JSKN003, JSKN033 (combo of JSKN003 and envafolimab) | HER2, HER2 | Full length Ab | Bispecific, Biparatopic | Humanized | TBD | TBD | ADC | Undisclosed | Undisclosed | TBD | Phase 3 | Breast cancer | Cancer | Alphamab (Australia) Co Pty Ltd. | ||
KB003 | Lenzilumab | GM-CSF | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 2/3 | Chronic Myelomonocytic Leukaemia (PREACH-M) | Immune-mediated / inflammatory disorders | Humanigen | |||
KHK4083, AMG451 | Rocatinlimab | OX40 | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 3 | Atopic dermatitis (NCT05398445, NCT05633355, NCT05651711, NCT05724199, NCT05704738, NCT05882877, NCT05899816) | Immune-mediated / inflammatory disorders | Kyowa Hakko Kirin | Amgen | ||
Kintuximab, gentuximab, cintuximab (not WHO assigned INN) | VEGFR2 | Full length Ab | Monospecific | Chimeric | TBD | TBD | Unconjugated | TBD | Phase 3 | Advanced gastric or gastroesophageal junction adenocarcinoma (CTR20220815) | Cancer | GeneScience Pharmaceuticals Co. Ltd. | Changchun Jinsai Pharmaceutical Co. Ltd. | |||
KN026 | Anbenitamab | HER2, HER2 | Full length Ab | Bispecific, Biparatopic | Humanized | IgG1 | kappa | Unconjugated | Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly) | Phase 3 | Gastric (NCT05427383), breast cancer (NCT05838066) | Cancer | Jiangsu Alphamab Biopharmaceuticals Co. Ltd | Sanofi | ||
KN046 | Erfonrilimab | PD-L1, CTLA-4 | Fragment-Fc - 2+2 symmetric, (VHH-VHH')2-Fc, Tandem-VHH-Fc | Bispecific | Chimeric, Humanized | IgG1 | NA | Unconjugated | Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly) | Phase 3 | Non-small-cell lung cancer (NCT04474119), Advanced Pancreatic Ductal Adenocarcinoma (NCT05149326) | Cancer | Alphamab (Australia) Co Pty Ltd. | Pfizer, Zelgen, Sunny Lake, Kintor, Sinovent, InxMed | ||
KN057 | Tissue factor pathway inhibitor | TBD | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 3 | Hemophilia A and Hemophilia B | Cardiovascular / hemostasis disorders | Suzhou Alphamab Biotechnology Co. Ltd | Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. | |||
KSI-301, OG1953 | Tarcocimab tedromer | VEGF-A | Full length Ab conjugate - ABC | Monospecific | Humanized | IgG1 | kappa | Immunoconjugate | Biopolymer | L234A, L235A, G237A (impair Fc effector functions), L443C | Phase 3 | Non-proliferative Diabetic Retinopathy (NCT06270836) | Ophthalmic disorders | Kodiak Sciences Inc | ||
L19-TNF, L19TNF, L19(scFv)2-TNF | Onfekafusp alfa | Fibronectin EDB, TNF | Fragment fusion - scFv-TNF | Monospecific | Human | NA | TBD | Immunoconjugate - Immunocytokine | TNF | NA | Phase 3 | Soft tissue sarcoma (NCT04650984) | Cancer | Philogen S.p.A. | Sun Pharma, Merck Sharp & Dohme | |
LMN-201 | C. difficile (exotoxin TcdB) | Fragment - sdAb, VHH dimers | Mixture of 3 monospecific antibodies | TBD | NA | NA | Unconjugated | NA | Phase 2/3 pending | Clostridioides difficile infection (NCT05330182 not yet recruiting) | Infectious diseases | Lumen Bioscience Inc. | ||||
LY3372993 | Remternetug | Amyloid beta (N3pG) | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 3 | Alzheimer's Disease (NCT05463731) | Neurological disorders | Eli Lilly and Company | |||
M1095, MSB0010841, ALX-0761 | Sonelokimab | IL-17A, IL17F, Albumin | Fragment - sdAb, VHH-VHH'-VHH | Multispecific, Trispecific | Humanized | NA | NA | Unconjugated | NA | Phase 3 | Hidradenitis Suppurativa (NCT06411899, NCT06411379) | Immune-mediated / inflammatory disorders | Merck Serono | MoonLake Immunotherapeutics AG, Bond Avillion 2 Development LP | ||
M701 | EpCAM, CD3 | Fragment-Fc - YBODY | Bispecific | Chimeric | TBD | TBD | Unconjugated | TBD | Phase 3 | Malignant ascities (NCT06432296) | Cancer | Wuhan YZY Biopharma Co. Ltd. | ||||
MAA868, NOV-12 | Abelacimab | Factor XI | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | D265A P329A. Reduced effector functions | Phase 3 | Venous thromboembolism (NCT05171075, NCT05171049), Atrial Fibrillation (NCT05712200) | Cardiovascular / hemostasis disorders | Novartis Pharmaceuticals | Anthos Therapeutics, MorphoSys | ||
Mab-B43.13 | Oregovomab | MUC16 | Full length Ab | Monospecific | Murine | IgG1 | kappa | Unconjugated | None found | Phase 3 | Ovarian cancer (NCT04498117) | Cancer | OncoQuest, Quest PharmaTech Inc. | CanariaBio Inc., Hikma Pharmaceuticals PLC, Dual Industrial Co. Ltd., Unither Pharmaceuticals, Virexx, Biomira Inc. | ||
MEDI3506 | Tozorakimab | IL-33 | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | None found | Phase 3 | Chronic obstructive pulmonary disease (NCT05166889, NCT05158387, NCT05742802); Acute respiratory failure (NCT05624450) | Respiratory diseases | AstraZeneca | |||
MEDI5752 | Volrustomig | CTLA-4, PD-1 | Full length Ab | Bispecific | Human | IgG1 | kappa/lambda | Unconjugated | Reduced effector functions | Phase 3 | Cervical cancer (NCT06079671); Non-small cell lung cancer (NCT05984277) | Cancer | AstraZeneca | |||
MEDI9447 | Oleclumab | CD73 | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | L234F, L235E, P331S (reduced effector function) | Phase 3 | Non-small cell lung cancer (NCT05221840) | Cancer | AstraZeneca | |||
Meplazumab, HP6H8 | CD147 | Full length Ab | Monospecific | Humanized | IgG2 | TBD | Unconjugated | TBD | Phase 3 | COVID-19 (NCT05113784, NCT04586153, NCT05679479); post-COVID-19 (NCT05813587) | Immune-mediated / inflammatory disorders | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | ||||
MGC018 | Vobramitamab duocarmazine | B7-H3 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Valine-citrulline–seco (Cleavable linker) | Duocarmycin | None found | Phase 2/3 | Prostate cancer (NCT05551117 TAMARACK) | Cancer | Macrogenics | |
MIL62 | CD20 | Full length Ab | Monospecific | Humanized | TBD | TBD | Unconjugated | Afucosylated (improve FcγRIIIa binding/improve ADCC) | Phase 3 | Neuromyelitis optica spectrum disorder (NCT05314010); Follicular lymphoma and marginal zone lymphoma (NCT04834024); Systemic Lupus Erythematosus (NCT05796206) | Cancer | Beijing Mabworks Biotech Co. Ltd. | ||||
MK-1308, AK107 | Quavonlimab | CTLA-4 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Renal cell carcinoma (NCT04736706, NCT05899049) | Cancer | Akeso Inc. | Merck | ||
MK-1654 | Clesrovimab | RSV (F glycoprotein) | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | M252Y, S254T, T256E (half life extension) | Phase 3 | Reduction in incidence of respiratory syncytial virus infection (NCT04767373, NCT04938830) | Infectious diseases | Merck | |||
MK-4280 | Favezelimab | LAG-3 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Hodgkin lymphoma (NCT05508867); Colorectal cancer (NCT05600309, NCT05064059) | Cancer | Merck Sharp & Dohme Corp | |||
MK-7684 | Vibostolimab | TIGIT | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Non-small cell lung cancer (NCT04738487; NCT05298423; NCT05226598); Small cell lung cancer (NCT05224141); Melanoma (NCT05665595) | Cancer | Merck Sharp & Dohme Corp. | |||
MRG002 | HER2 | Full length Ab | Monospecific | Humanized | IgG1 | TBD | ADC | Valine-Citrulline (Cleavable linker) | MMAE | Hyperfucosylated (reduce Fc𝛾RIIIa binding/reduce ADCC) | Phase 3 | Breast Cancer (NCT04924699) | Cancer | LEPU Biopharma, Shanghai Miracogen Inc. | ||
MRG003 | EGFR | Full length Ab | Monospecific | Human | IgG1 | TBD | ADC | Valine-Citrulline (Cleavable linker) | MMAE | TBD | Phase 3 | Squamous Cell Carcinoma of the Head and Neck (NCT05751512) | Cancer | LEPU Biopharma, Shanghai Miracogen Inc. | ||
MTIG7192A, RO7092284, RG6058 | Tiragolumab | TIGIT | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | None found | Phase 3 | Non-small cell lung cancer (NCT04294810, NCT04513925, NCT04619797); Esophageal cancer (NCT04543617, NCT04540211) | Cancer | Genentech | |||
NEOD001; murine parent is 2A4 | Birtamimab | Amyloid light chain | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Light chain (AL) amyloidosis (NCT04973137) | Cardiovascular / hemostasis disorders | Onclave Therapeutics Limited | Prothena | ||
NN-7769, NNC0365-3769, Mim8 | Denecimig | Factor IXa, Factor X | Full length Ab - Duobody | Bispecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Hemophilia A with or without inhibitors (NCT05306418, NCT05053139, NCT05685238, NCT05878938) | Cardiovascular / hemostasis disorders | Novo Nordisk | Genmab | ||
NN8765, IPH-2201, NNC141-0100 | Monalizumab | NKG2A | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Squamous Cell Carcinoma of the Head and Neck (NCT04590963); Non-small Cell Lung Cancer (NCT05221840) | Cancer | Novo Nordisk | AstraZeneca, Innate Pharma | ||
PB2452, MEDI2452 | Bentracimab | Ticagrelor | Fragment - Fab | Monospecific | Human | NA | lambda | Unconjugated | None found | Phase 3 | Reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure (NCT04286438) | Cardiovascular / hemostasis disorders | AstraZeneca | PhaseBio Pharmaceuticals Inc, Alfasigma, SFJ Pharmaceuticals, SERB Pharmaceuticals | ||
PF-06801591 | Sasanlimab | PD-1 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Non-muscle invasive bladder cancer (NCT04165317) | Cancer | Pfizer | |||
PF-06823859, PF06823859 | Dazukibart | IFN beta | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | L234A, L235A, G237A (impair Fc effector functions) | Phase 3 | Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] (NCT05895786) | Immune-mediated / inflammatory disorders | Pfizer | |||
PF-07940370, RO4905417, RG1512 | Inclacumab | P-selectin | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization); L235E (impair Fc effector function) | Phase 3 | Vaso-occlusive crisis in sickle cell disease patients (NCT05348915, NCT04927247, NCT04935879) | Cardiovascular / hemostasis disorders | Hoffmann-La Roche | Pfizer | ||
PM8002, BNT327 | PD-L1, VEGF A | Appended Ig - VHH-IgG | Bispecific | TBD | IgG1 | TBD | Unconjugated | Fc silencing mutations (specific ones unknown); anti-PDL1 VHH fused to the antibody to become bispecific | Phase 2/3 | Non-small Cell Lung Cancer (NCT05756972); Small Cell Lung Cancer (NCT05844150) | Cancer | Biotheus Inc. | BioNTech | |||
PRA023, MK-7240 | Tulisokibart | TL1a | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | L234A, L235A, P329A (impair Fc effector functions) | Phase 3 | Ulcerative colitis (NCT06052059) | Immune-mediated / inflammatory disorders | Merck Sharp & Dohme LLC | |||
QGE031 | Ligelizumab | IgE | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Food allergy (NCT05678959) | Immune-mediated / inflammatory disorders | Tanox | Novartis | ||
QX005N, SNC005 | IL-4R alpha | TBD | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 3 | Atopic dermatitis (CTR20241068), Nodular prurigo (CTR20241660 not yet recruiting) | Immune-mediated / inflammatory disorders | Jiangsu Qyuns Therapeutics Co. Ltd. | ||||
REGN2477 | Garetosmab | Activin A | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Fibrodysplasia ossificans progressiva (NCT05394116) | Skeletal disorders | Regeneron Pharmaceuticals | |||
REGN3500, SAR440340 | Itepekimab | IL-33 | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Chronic obstructive pulmonary disease (NCT04751487, NCT04701983) | Respiratory diseases | Regeneron Pharmaceuticals | |||
REGN3767 | Fianlimab | LAG-3 | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization); E233P, F234V, L235A, G236del (reduced effector function) | Phase 3 | Melanoma (NCT05352672, NCT05608291); Non-small Cell Lung Cancer (NCT05785767, NCT05800015) | Cancer | Regeneron Pharmaceuticals | Sanofi | ||
REGN5713-5714-5715 | Atisnolerbart, bremzalerbart, umesolerbart | Bet v 1 | Full length Ab | Mixture of 3 monospecific antibodies | Human | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Seasonal allergic rhinitis (NCT04709575) | Immune-mediated / inflammatory disorders | Regeneron Pharmaceuticals | |||
RO5509554, RG7155 | Emactuzumab | CSF-1R | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Tenosynovial giant cell tumor (NCT05417789) | Cancer | Hoffmann-La Roche | SynOx Therapeutics | ||
RO7187807, MSTT1041A, RG6149, AMG282 | Astegolimab | IL-33R | Full length Ab | Monospecific | Human | IgG2 | kappa | Unconjugated | None found | Phase 3 | Chronic obstructive pulmonary disease (NCT05595642, NCT05878769) | Immune-mediated / inflammatory disorders | Amgen | Genentech | ||
RO7200220, RG6179, EBI-031 | Vamikibart | IL-6 | Full length Ab | Monospecific | Humanized | IgG2 | kappa | Unconjugated | H310A (half life extension) | Phase 3 | Uveitic macular edema (NCT05642325, NCT05642312) | Ophthalmic disorders | Sesen Bio | Hoffmann-La Roche | ||
RO7204239, GYM329, RG6237 | Myostatin | Full length Ab | Monospecific | TBD | TBD | TBD | Unconjugated | Specific mutations not found; engineered for selective and enhanced binding to the human FcγRIIb and for stronger affinity to FcRn in acidic pH conditions | Phase 2/3 | Spinal muscular atrophy (NCT05115110) | Neurological disorders | Chugai Pharmaceutical Co. Ltd. | ||||
RZ358, XOMA 358, XMetD | Ersodetug | Insulin receptor | Full length Ab | Monospecific | Human | IgG2 | kappa | Unconjugated | None found | Phase 3 | Congenital hyperinsulinism | Metabolic disorders | XOMA | Rezolute Inc | ||
SAR441344, INX-021 | Frexalimab | CD40L | Full length Ab | Monospecific | Chimeric | IgG1 | kappa | Unconjugated | V215A E269R K322A (enhanced effector functions) | Phase 3 | Multiple sclerosis (NCT06141473, NCT06141486) | Immune-mediated / inflammatory disorders | ImmuNext | Sanofi | ||
SAR445088, BIVV020 | Riliprubart | Complement C1s | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | TBD | Phase 3 | Inflammatory Demyelinating Polyneuropathy (NCT06290128, NCT06290141) | Immune-mediated / inflammatory disorders | Sanofi | |||
SAR445229, KY1005 | Amlitelimab | OX40L | Full length Ab | Monospecific | Human | IgG4 | kappa | Unconjugated | S228P (hinge stabilization), L235E ( reduce effector function) | Phase 3 | Atopic dermatitis (NCT06130566) | Immune-mediated / inflammatory disorders | Sanofi | |||
SCT-I10A, SCTI-10A | Finotonlimab | PD-1 | Full length Ab | Monospecific | Humanized | IgG4 | kappa | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Hepatocellular carcinoma (NCT04560894); Non-small-cell lung cancer (NCT04171284); Head and neck squamous cell carcinoma (NCT04146402) | Cancer | Sinocelltech Ltd | |||
SGN-B6A | Sigvotatug vedotin | Integrin beta-6 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Valine-Citrulline (Cleavable linker) | MMAE | None found | Phase 3 | Non-small cell lung cancer (NCT06012435) | Cancer | Seagen Inc. | |
SHR-1701 | Retlirafusp alfa | PD-L1, TGF beta | Full length Ab fusion - IgG-(TGFbeta-R2-ECD)2 | Bispecific | Human | IgG4 | kappa | Immunoconjugate | TGF-β receptor II | S228P (hinge-stabilization) | Phase 3 | Cervical cancer (NCT05179239); Colorectal cancer (NCT04856787); Gastric or gastroesophageal junction cancer (NCT04950322); Non-small cell lung cancer (NCT05132413 not yet recruiting); Perioperative treatment of resectable gastric or gastroesophageal junction cancer (NCT05149807) | Cancer | Jiangsu HengRui Medicine Co. Ltd. | Suzhou Suncadia Biopharmaceuticals Co. Ltd. | |
SHR-1703 | IL-5 | TBD | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 2/3 | Eosinophilic Granulomatosis With Polyangiitis (NCT05979051) | Immune-mediated / inflammatory disorders | Jiangsu HengRui Medicine Co. Ltd. | Atridia Pty Ltd. | |||
SHR-A1811 | Trastuzumab rezetecan | HER2 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Undisclosed | Rezetecan | None found | Phase 3 | Breast cancer (NCT05424835, NCT05814354) | Cancer | Jiangsu HengRui Medicine Co. Ltd. | Suzhou Suncadia Biopharmaceuticals Co. Ltd. |
SHR-A1921 | TROP-2 | TBD | Monospecific | TBD | TBD | TBD | ADC | Undisclosed | Undisclosed | TBD | Phase 2/3 and Phase 3 pending | Ovarian cancer (NCT06211023 / CTR20240254) | Cancer | Shanghai Hengrui Pharmaceutical Co. Ltd. | Suzhou Suncadia Biopharmaceuticals Co. Ltd., Atridia Pty Ltd. | |
SI-B001 | Izalontamab | EGFR, HER3 | Appended Ig - 2+2 symmetric, IgG-(scFv)2 | Bispecific | Chimeric / Humanized | IgG1 | kappa/lambda | Unconjugated | None found | Phase 2/3 | Non-small cell lung cancer (NCT05020769) | Cancer | Sichuan Biokin Pharmaceutical | SystImmune Inc., Sichuan Baili Pharmaceutical Co. Ltd | ||
SRK-015 | Apitegromab | Myostatin | Full length Ab | Monospecific | Human | IgG4 | lambda | Unconjugated | S228P (hinge-stabilization) | Phase 3 | Spinal muscular atrophy (NCT05156320) | Muscular disorders | Scholar Rock | |||
SSGJ-601, 601 | VEGF-A | Full length Ab | Monospecific | Humanized | TBD | TBD | Unconjugated | TBD | Phase 3 | Branch retinal vein occlusion (NCT05520177) | Ophthalmic disorders | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd | ||||
SSGJ-608, 608 | IL-17A | Full length Ab | Monospecific | TBD | TBD | TBD | Unconjugated | TBD | Phase 3 | Psoriasis (NCT05536726) | Immune-mediated / inflammatory disorders | 3SBio | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. | |||
SSGJ-611, 611 | IL-4R alpha | Full length Ab | Monospecific | Humanized | IgG4 | TBD | Unconjugated | TBD | Phase 3 | Atopic dermatitis (NCT06173284) | Immune-mediated / inflammatory disorders | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd | 3SBio | |||
SSGJ-613 | IL-1 beta | TBD | Monospecific | Humanized | TBD | TBD | Unconjugated | TBD | Phase 3 | Gouty arthritis (CTR20233982) | Immune-mediated / inflammatory disorders | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. | 3SBio | |||
STRO-002 | Luveltamab tazevibulin | FR alpha | Full length Ab | Monospecific | Human | IgG1 | kappa | ADC | Valine citrulline p-aminobenzyl carbamate linker functionalized with dibenzocyclooctyne (DBCO) (Cleavable linker) | SC209 (Hemiasterlin) | Y180pAMF, F404pAMF (non-natural amino acid for site specific conjugation) | Phase 2/3 | Ovarian Cancer, Fallopian Tube Cancer (NCT05870748) | Cancer | Sutro Biopharma | Tasly Biopharmaceuticals Co. Ltd. |
SYN023, CTB011, CTB012 | Mazorelvimab, Zamerovimab | Rabies virus (glycoprotein) | Full length Ab | Mixture of 2 monospecific antibodies | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Rabies (NCT04644484) | Infectious diseases | Synermore Biologics Co. Ltd. | |||
TJ004309, TJ4309, TJD5 | Uliledlimab | CD73 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | N297A (Fc-aglycosylated) | Phase 2/3 | Non-small cell lung cancer (CTR20240650) | Cancer | TRACON Pharmaceuticals | I-Mab Biopharma | ||
TJ202, MOR202, MOR03087 | Felzartamab | CD38 | Full length Ab | Monospecific | Human | IgG1 | lambda | Unconjugated | None found | Phase 3 | Multiple myeloma (NCT03952091) | Cancer | MorphoSys AG | Human Immunology Biosciences Inc. (HIBio), I-Mab Biopharma | ||
TLX591, ATL-101, Lu-177-huJ591, Rosopatamab-177Lu-DOTA | Rosopatamab tetraxetan 177Lu | PSMA | Full length Ab | Monospecific | Humanized | IgG1 | kappa | RIC | Lu-177 | None found | Phase 3 | Prostate cancer (NCT04876651) | Cancer | Telix Pharmaceuticals Ltd | ||
TNM001 | RSV (F glycoprotein) | Full length Ab | Monospecific | Human | TBD | TBD | Unconjugated | TBD | Phase 2/3 | Preventing lower respiratory tract infections caused by respiratory syncytial virus in infants (NCT06083623) | Infectious diseases | Zhuhai Trinomab Biotechnology Co Ltd. | ||||
UB-421, dB4C7 mAb | Semzuvolimab | CD4 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | N297H (Fc-aglycosylated to remove Fc effector function) | Phase 3 | HIV infection (NCT04406727 not yet recruiting) | Infectious diseases | United Biopharma | |||
UX143, BPS804, MOR05813 | Setrusumab | Sclerostin | Full length Ab | Monospecific | Human | IgG2 | lambda | Unconjugated | None found | Phase 3 | Osteogenesis imperfecta (NCT05125809, NCT05768854) | Skeletal disorders | Mereo BioPharma Group plc | Ultragenyx Pharmaceutical Inc. | ||
VAY736, NOV-5 | Ianalumab | BAFFR | Full length Ab | Monospecific | Human | IgG1 | kappa | Unconjugated | Afucosylated (improve FcγRIIIa binding/improve ADCC) | Phase 3 | Sjogren syndrome (NCT05350072, NCT05349214); Autoimmune hepatitis (NCT03217422); Lupus nephritis (NCT05126277); Systemic Lupus Erythematosus (NCT05624749, NCT05639114); Warm Autoimmune Hemolytic Anemia (wAIHA) (NCT05648968); Primary Immune Thrombocytopenia (ITP) (NCT05653349, NCT05653219) | Immune-mediated / inflammatory disorders | Novartis Pharmaceuticals | |||
VIS649 | Sibeprenlimab | APRIL | Full length Ab | Monospecific | Humanized | IgG2 | kappa | Unconjugated | None found | Phase 3 | IgA nephropathy (NCT05248646; NCT05248659) | Immune-mediated / inflammatory disorders | Otsuka Pharmaceutical Development & Commercialization Inc. | |||
VLS-101, MK-2140 | Zilovertamab vedotin | ROR1 | Full length Ab | Monospecific | Humanized | IgG1 | kappa | ADC | Valine-citrulline (Maleimidocaproyl-valine-citrulline-para-aminobenzoate; Cleavable linker) | MMAE | None found | Phase 2/3 | Diffuse large B-cell lymphoma (NCT05139017) | Cancer | Merck Sharp & Dohme LLC | |
VYD222 | Pemivibart | SARS-CoV-2 (spike protein) | TBD | Monospecific | Human | IgG1 | lambda | Unconjugated | Half-life extension | Phase 3, Emergency use authorization | COVID-19 (NCT06039449) | Infectious diseases | Invivyd Inc. | |||
XKH004, LZM-012, LZM012 | IL-17A, IL-17F | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | TBD | Phase 3 | Psoriasis (NCT06110676) | Immune-mediated / inflammatory disorders | Xinkanghe Biomedicine | Livzon Pharmaceutical Group Inc. | |||
ZB001, VRDN-001, IMGN164, AVE1642 | Veligrotug | IGF-1R | Full length Ab | Monospecific | Humanized | IgG1 | kappa | Unconjugated | None found | Phase 3 | Thyroid Eye Disease (NCT05176639) | Immune-mediated / inflammatory disorders | Sanofi | Zenas Biopharma, miRagen | ||
ZB012, XMAB5871 | Obexelimab | CD19 | Full length Ab | Bispecific | Humanized | IgG1 | kappa | Unconjugated | S267E, L328F (increase binding to FcγRIIb) | Phase 3 | IgG4 Related Disease (NCT05662241); Warm Autoimmune Hemolytic Anemia (NCT05786573 not yet recruiting) | Immune-mediated / inflammatory disorders | Xencor | Bristol Myers Squibb, Zenas BioPharma Ltd, Amgen |
Table notes:
- in the “Backbone” column, the isotype refers to human unless indicated otherwise with the prefix m- (murine) or r- (rat).
- in the “Format” column is reported format and format details.
- information on general molecular category (ADC, RIC, immunoconjugates, immunocytokines, unconjugated) and details is reported in the column “Conjugated/Fused”.